Adipokines and metabolic parameters in patients with type 2 diabetes mellitus in combination with gout
https://doi.org/10.14341/omet2016120-24
Abstract
Aim. To study the impact of type 2 diabetes and its combination with gout on the level of adipokines, hormonal and metabolic parameters.
Materials and methods. The study included 18 men with type 2 diabetes with a mean age 57,83 ± 1,67 years, and 21 subjects with a combination of type 2 diabetes and gout, whose average age was 57,57 ± 1,44 years. The controls were 40 healthy men: 20 subjects with an average age of 21,03 ± 0,15 years and 20 men with average age 51,31 ± 1,34 years. All patients had anthropometric measurements, evaluation of parameters of lipid and carbohydrate metabolism, uric acid, levels of adiponectin, leptin and resistin.
Results. Patients of both groups had elevated concentrations of leptin, resistin and reduced level of adiponectin. Men with type 2 diabetes, and its combination with gout had increased levels of total cholesterol, triglycerides, glucose and insulin.
Conclusion. In patients with type 2 diabetes, and its combination with gout are characterized by hyperleptinemia, hypererresistinemia, hypooadiponectinemia. Insulin resistance with compensatory hyperinsulinemia and atherogenic dyslipidemia was found in all patient groups.
About the Authors
Andrey F. Verbovoy
Samara State Medical University
Russian Federation
MD, PhD, professor, Head of the Endocrinology department
Russian Federation
MD, PhD, professor, Head of the Endocrinology department
Irina A. Tsanava
Samara State Medical University
Russian Federation
Senior assistant of the Endocrinology department
Russian Federation
Senior assistant of the Endocrinology department
Nelli I. Verbovaya
Samara State Medical University
Russian Federation
MD, PhD, professor
Russian Federation
MD, PhD, professor
References
1. Эндокринология. Национальное руководство. / Под ред. Дедова И.И., МельниченкоГ.А.. — М.: ГЭОТАР-Медиа; 2009. – 373 с. [Endokrinologiya. Natsional'noe rukovodstvo. Ed. by. Dedov II, Mel'nichenko GA. Moscow: GEOTARMedia; 2009. (In Russ).]
2. International Diabetes federation, Diabetes Atlas 6th ed. International Diabetes Federation; 2014.
3. Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? The Journal of rheumatology. 2002;29(11):2403-6.
4. Дедов И.И., Шестакова М.В., Александров А.А., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (6-й выпуск) // Сахарный диабет. - 2013. - Т. 16. - №1S - C. 1-120. [Dedov II, Shestakova MV, Aleksandrov AA, et al. Standards of specialized diabetes care. Ed. by Dedov II, Shestakova MV (6th edition). Diabetes mellitus. 2013;16(1S):1-120. (In Russ.)]doi: 10.14341/DM20131S1-121
5. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis & Rheumatism. 1977;20(3):895-900.
6. Барскова В.Г., Елисеев М.С., Насонов Е.Л., и др. Синдром инсулинорезистентности у больных подагрой и его влияние на формирование клинических особенностей болезни. // Терапевтический архив. – 2004 – Т. 76 – № 5 – С. 51-56. [Barskova VG, Eliseev MS, Nasonov EL, et al. Sindrom insulinorezistentnosti u bol'nykh podagroi i ego vliyanie na formirovanie klinicheskikh osobennostei bolezni. Terapevticheskii arkhiv. 2004; 76(5): 51-56. (In Russ).]
7. Барскова В.Г., Елисеев М.С., Насонов Е.Л., и соавт. Применение метформина (Сиофор®) у пациентов с подагрой и инсулинорезистентностью (предварительные данные 6-месячного наблюдения). // Терапевтический архив. – 2005. – Т. 77. – №12 – С. 44-49. [Barskova VG, Eliseev MS, Nasonov EL, et al. Primenenie metformina (Siofor®) u patsientov s podagroi i insulinorezistentnost'yu (predvaritel'nye dannye 6-mesyachnogo nablyudeniya). Terapevticheskii arkhiv. 2005; 77(12):44-49. (In Russ).]
8. Барскова В.Г., Ильиных Е.В., Елисеев М.С., и др. Кардиоваскулярный риск у больных подагрой // Ожирение и метаболизм. – 2006. – Т. 3. – №3 – C. 40-44. [Barskova VG, Il'inykh EV, Eliseev MS, et al. Kardiovaskulyarnyy risk u bol'nykh podagroy. Obesity and metabolism. 2006;3(3):40-44. (In Russ).] doi: 10.14341/2071-8713-5263
9. Барскова В.Г., Елисеев М.С., Зилов А.В., Насонов Е.Л. Влияние гипергликемии и гиперинсулинемии на уровень мочевой кислоты и течение артрита у больных подагрой с сахарным диабетом 2 типа // Ожирение и метаболизм. – 2007. – Т. 4. – №1 – C. 19-23. [Barskova VG, Eliseev MS, Zilov AV, Nasonov EL. Vliyanie giperglikemii i giperinsulinemii na uroven' mochevoy kisloty i techenie artrita u bol'nykh podagroy s sakharnym diabetom 2 tipa. Obesity and metabolism. 2007;4(1):19-23. (In Russ).] doi: 10.14341/2071-8713-4908
10. Елисеев М.С., Барскова В.Г., Насонов Е.Л., и др. Особенности подагры, протекающей с сахарным диабетом II типа. // Клиническая геронтология. – 2005. – Т. 11 – № 4 – С. 7-13. [Eliseev MS, Barskova VG, Nasonov EL, et al. Osobennosti podagry, protekayushchei s sakharnym diabetom II tipa. Klinicheskaya gerontologiya. 2005;11(4):7-13. (In Russ).]
11. Мадянов И.В., Илюхина О.Б. Особенности мочекислого обмена при сахарном диабете 2 типа. // Терапевт. – 2014. – № 1. – С. 11-14. [Madyanov IV, Ilyukhina OB. Osobennosti mochekislogo obmena pri sakharnom diabete 2 tipa. Terapevt. 2014;1:11-14. (In Russ).]
12. Мадянов И.В. Особенности пуринового обмена на этапах развития и прогрессирования сахарного диабета (диагностические, патогенетические и лечебные аспекты): Дис. … докт. мед. наук. – М.; 1999. [Madyanov I.V. Osobennosti purinovogo obmena na etapakh razvitiya i progressirovaniya sakharnogo diabeta (diagnosticheskie, patogeneticheskie i lechebnye aspekty): [Dissertation]. Moscow.; 1999. (In Russ).]
13. Соломонова Е., Вербовой А. Жировая ткань и адипокины. // LAP LAMBERT Academic Publishing – Saarbriicken. – 2012. – 124 c. [Solomonova E, Verbovoi A. Zhirovaya tkan' i adipokiny. LAP LAMBERT Academic Publishing – Saarbriicken. 2012.]
Supplementary files
Review
For citations:
Verbovoy A.F., Tsanava I.A., Verbovaya N.I. Adipokines and metabolic parameters in patients with type 2 diabetes mellitus in combination with gout. Obesity and metabolism. 2016;13(1):20-24. (In Russ.) https://doi.org/10.14341/omet2016120-24
Views:
1127
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
